Non Invasive Prenatal Testing Market Segmentation:
Gestational Age Segment Analysis
13-24 weeks segment is poised to account for non invasive prenatal testing market share of more than 51.4% by the end of 2035. The segment is leading as detection in the second trimester provides an optimal window between detection and test accuracy. This timeframe is also easily combined with other crucial prenatal screening tests, such as ultrasound and serum screening for alpha-fetoprotein.
A recent development related to this was by Illumina, Inc. in January 2024 when they launched VeriSeq NIPT Solution v2. This new solution enables the test to detect partial deletions and duplications of all chromosomes with the test, greatly enhancing its power to recognize a wider range of genetic anomalies during these critical weeks from 13-24.
Method Segment Analysis
The maternal cell-free DNA segment in non invasive prenatal testing market is projected to grow at lucrative CAGR through 2035. The growth of the segment is propelled by technological advancements that extend the testing capabilities to whole genome sequencing for the detection of microdeletions and sex chromosomal abnormalities. Increasing product launches and improving reimbursement scenarios also contribute to NIPT market growth and both, directly and indirectly make these tests accessible to a larger population.
As per a report from the National Institutes of Health in August 2023, the adoption rate for cfDNA-based NIPT is over 75% among pregnant women in high-income countries. This represents an increase of 15% from that reported in 2022 and outlines the acceptance and integration of NIPT into standard prenatal care protocols. To tap into the opportunity, companies are launching various innovative tests.
For example, in March 2024, Roche announced the launch of its HARMONY prenatal test with expanded capabilities. Innovations like these from companies enable extra rare chromosomal conditions, allowing more inclusively rounded insight into fetal health during pregnancy.
Our in-depth analysis of the global non invasive prenatal testing market includes the following segments:
|
Gestational Age |
|
|
Pregnancy Risk |
|
|
Method |
|
|
Technology |
|
|
Product |
|
|
Application |
|
|
End user |
|
